HY2900 HIFU for Uterine Fibroids
Non-invasive focused ultrasound system for organ-preserving treatment of uterine fibroids and adenomyosis
Focused Ultrasound Therapy (HIFU)
Focused ultrasound therapy (HIFU) is performed under medical imaging guidance, concentrating ultrasound waves on an internal target region to form a high–energy‑density focal point. The focal tissue temperature rises rapidly, producing coagulative necrosis within a very short time, while tissue outside the focus shows no obvious damage. By controlling the three‑dimensional movement of the focal point, conformal treatment of the entire target tissue is achieved.
Focused ultrasound (HIFU) technology has been explored clinically in indications such as uterine fibroids, adenomyosis, benign prostatic hyperplasia, breast nodules, endometriosis, and scar pregnancy.
The HY2900 system is specifically designed and clinically configured for non-invasive, uterus‑preserving treatment of uterine fibroids and adenomyosis.
Why HY2900?
The HY2900 High Intensity Focused Ultrasound (HIFU) system is a non-invasive therapeutic platform for the treatment of uterine fibroids and adenomyosis.
Safe
No medical accidents have been reported to date in clinical use of the HY2900 system.
Patients can start planning pregnancy six months after treatment.
Treatment enables early intervention and supports women with future pregnancy plans, including those planning a second child.
Effective
Ablation with consequent coagulative necrosis was achieved in 100% of treated lesions.
At 6 months post‑treatment, 73% of tumors show a volume reduction of at least 50%.
Clinical symptoms improve effectively.
Treatment enables intervention before fibroids reach traditional surgical thresholds, reducing future need for hysterectomy or myomectomy.
Precise
Focal spot accuracy: 1.2 × 1.2 × 8 mm³
Five‑axis mechanical scanning accuracy: 0.1 mm.
Phased‑array technology.
Crown‑shaped treatment mode (proprietary technology)
Patient-friendly
No skin incision, no intraoperative bleeding and scarring.
Avoids many complications of open or laparoscopic surgery
Performed without general anesthesia
Continuous communication between physician and patient during the procedure
Treatment can be performed by a single physican/gynecologist.
Clinical Cases for HY2900 HIFU
Patient 1 —— single posterior wall fibroid
Progressive volume reduction of a single posterior wall fibroid with sustained non-perfusion at 6-month follow-up, consistent with effective coagulative necrosis and tissue resorption.
Age: 47
Diagnosis: Uterine fibroid
Symptoms: Heavy menstrual flow, shortened menstrual cycle, prolonged menstrual period, anemia
POST-TREATMENT
6-MONTH FOLLOWUP
BASELINE
MRI Comparison:
BASELINE Lesion in the posterior uterine wall, approximately 78×75×68 mm, well‑defined low‑echo area with inhomogeneous moderate contrast enhancement.
POST-TREATMENT Posterior uterine wall lesion approximately 78×76×70 mm with a well‑defined, round non‑perfused region of 76×75×70 mm and moderate peripheral enhancement on contrast scan.
6-MONTH FOLLOWUP Posterior uterine wall lesion reduced to approximately 38×38×35 mm, with a well‑defined, round non‑perfused region of 38×38×32 mm and moderate peripheral enhancement on contrast scan.
Volume reduction from 78×75×68mm to 38×38×35mm.
Patient 2 —— multiple fibroids
Successful treatment of multiple fibroids with immediate absence of contrast enhancement in treated lesions, indicating complete ablation despite complex fibroid distribution.
BASELINE
Age: 49
Diagnosis: Multiple uterine fibroids
Symptoms: Prolonged menstrual periods with heavy flow, moderate anemia.
POST-TREATMENT
MRI Comparison:
BASELINE Distorted uterine contour with multiple round abnormal signals of varying sizes in the intramural and subserosal layers, largest about 50×47 mm, moderately well‑defined with moderate progressive contrast enhancement.
POST-TREATMENT After contrast administration, no obvious enhancement in the lesions; the largest lesion (about 54×51 mm) shows clear coagulative necrosis compared with pre‑treatment.
Absent enhancement confirms clear coagulative necrosis of the largest lesion.
Patient 3 —— adenomyosis
Treatment of adenomyosis with significant reduction in lesion enhancement, correlating with expected symptom relief in this chronic condition.
Age: 41
Diagnosis: Uterine adenomyoma
Symptoms: Dysmenorrhea for over 3 years, heavy menstrual flow, moderate anemia.
BASELINE
POST-TREATMENT
MRI Comparison:
BASELINE Lesion in the anterior uterine wall approximately 66×51×43 mm, round abnormal signal, poorly defined, with marked enhancement after contrast administration.
POST-TREATMENT Minimal enhancement within the lesion after contrast-enhanced scan, size approximately 61×49×40 mm.
Lesion shrinkage from 66×51×43 mm to 61×49×40 mm indicates effective ablation and treatment response.
HY2900 Clinical Demonstration
Watch how HY2900 enables non-invasive, uterus-preserving treatment in a clinical setting.
About Us
LIANSHENG MEDTECH is a Shanghai‑based export partner and the exclusive global distributor of the HY2900 high‑intensity focused ultrasound (HIFU) system for uterus‑preserving treatment of uterine fibroids and adenomyosis. The HY2900 is developed and manufactured by Wuxi Haiying Medical Technology Co., Ltd. （无锡海鹰医疗科技股份有限公司）, with LIANSHENG serving as the single point of contact for overseas distributors and hospitals.
LIANSHENG MEDTECH is partly owned by Chance Non‑invasive (辰时无创), which operates HY2900‑based HIFU centers across China and is the exclusive clinical operator of this device in the domestic market. Through this collaboration among the manufacturer (Haiying), the clinical operator (Chance Non‑invasive), and the global distributor (LIANSHENG MEDTECH), international partners gain access not only to the HY2900 device, but also to structured training, case examples, and operating know‑how drawn from more than 20 active HIFU clinics in China.
Follow Us On Social